Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT(R) (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Filing supported by data from MERIT-1 trial evaluating OPSUMIT in adults with inoperable CTEPH which showed significant improvements in pulmonary vascular resistance and six-minute walk distance (6MWD) compared with ongoing background therapy CHERRY HIL... Biopharmaceuticals, FDA Actelion Pharmaceuticals, Janssen, Johnson & Johnson, OPSUMIT, macitentan
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news